95% CI, 0.44-0.77), esophageal cancer (HR = 0.6
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed to manage type 2 diabetes mellitus
Glueck CJ, Aregawi D, Goldenberg N, Golnik KC, Sieve L, Wang P
GIP/GLP-1 GIP/GLP-120234 2 20244 GLP-1SURPASS-J-MONOBMI 2652HbA1c HbA1c 7.094 2.5mg45mg7.5mg10mg12.5mg15mg5mg1384834461712807 433368 GLP-1 GIPGLP-1 1970-1980GIPGLP-1GLP-1GLP-1GLP-1GLP-1GLP-1 GIP GIPGLP-1 DPP4GIPGLP-1GLP-1GIP GIPGLP-1GIPGIPGLP-1GIPGLP-1DPP4GIPGLP-1 1.0mgGIPGLP-1GIPGIP
Patients taking multiple medications should discuss potential interactions, though GLP-1 receptor agonists have minimal hepatic metabolism interactions
no clinically relevant pharmacokinetic interactions between these stimulants and standard second-generation antihistamines are expected based on current UK SmPCs and BNF guidance